Anti-tachycardia pacing in ARVC: should a transvenous or subcutaneous system be used?
暂无分享,去创建一个
[1] P. Lambiase,et al. Right ventricular function is a predictor for sustained ventricular tachycardia requiring anti-tachycardic pacing in arrhythmogenic ventricular cardiomyopathy: insight into transvenous vs. subcutaneous implantable cardioverter defibrillator insertion , 2023, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[2] J. Healey,et al. Perioperative Safety and Early Patient and Device Outcomes Among Subcutaneous Versus Transvenous Implantable Cardioverter Defibrillator Implantations , 2022, Annals of Internal Medicine.
[3] H. Calkins,et al. Subcutaneous and Transvenous Defibrillators in Arrhythmogenic Right Ventricular Cardiomyopathy: A Comparison of Clinical and Quality-of-Life Outcomes. , 2022, JACC. Clinical electrophysiology.
[4] T. Kurita,et al. Anti-tachycardia pacing success in implantable cardioverter defibrillators by patient, device, and programming characteristics. , 2022, Heart rhythm.
[5] Stefan L. Zimmerman,et al. A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy , 2022, European heart journal.
[6] H. Calkins,et al. Comparing clinical performance of current implantable cardioverter-defibrillator implantation recommendations in arrhythmogenic right ventricular cardiomyopathy , 2021, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[7] F. Sacher,et al. Outcomes after catheter ablation of ventricular tachycardia without implantable cardioverter-defibrillator in selected patients with arrhythmogenic right ventricular cardiomyopathy. , 2021, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[8] J. Svendsen,et al. Complications of implantable cardioverter-defibrillator treatment in arrhythmogenic right ventricular cardiomyopathy. , 2021, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[9] Stefan L. Zimmerman,et al. Sudden Cardiac Death Prediction in Arrhythmogenic Right Ventricular Cardiomyopathy , 2020, Circulation. Arrhythmia and electrophysiology.
[10] A. Wilde,et al. Implantable cardioverter-defibrillator harm in young patients with inherited arrhythmia syndromes: A systematic review and meta-analysis of inappropriate shocks and complications. , 2016, Heart rhythm.
[11] M. Link,et al. Ventricular arrhythmias in the North American multidisciplinary study of ARVC: predictors, characteristics, and treatment. , 2014, Journal of the American College of Cardiology.
[12] Wojciech Zareba,et al. Reduction in inappropriate therapy and mortality through ICD programming. , 2012, The New England journal of medicine.